Table 4. Relationships between IDRFs, tumor shape, initial volume, tumor volume decrease and genomic profile.
| Genomic profile(1) | NCA | SCA | MNA | Total | P-value | |
|---|---|---|---|---|---|---|
| N = | 50 | 47 | 36 | 133 | ||
| IDRF | 0 | 7 | 3 | 1 | 11 | .19 |
| + | 43 | 44 | 35 | 122 | ||
| IDRF number(2) (median, range) | 2 (1–8) | 3 (1–13) | 5 (1–14) | < .0001 | ||
| Tumor shape | single mass | 42 | 26 | 16 | 84 | .0003 |
| multiple confluent masses | 8 | 21 | 20 | 49 | ||
| Tumor volume at diagnosis median (range) in mL | 69 (3–553) | 151 (1–1040) | 524 (14–1626) | < .0001 | ||
| Tumor volume decrease median (range) | 79% (0%, 100%) | 81% (39%, 99%) | 96% (38%, 99%) | < .0001 | ||
| Number of patients treated with neoadjuvant chemotherapy | 37 | 41 | 35 | |||
(1) NCA: numerical-only chromosome alterations; SCA: segmental chromosome alterations; MNA: MYCN-amplification.
(2) IDRF number among the 122 IDRF-positive NBs.